406 Results for "

TAU

" in MedChemExpress (MCE) Product Catalog:
Products (406)

406 Results for "TAU" in MCE Product Catalog:

39
39 Publications Verification
Cat. No.: HY-13814
CAS No.: 2645-32-1
Purity:  99.26%
Research Areas:  

Cancer

PR-619 is a broad-range and reversible DUB inhibitor with EC50s of 3.93, 4.9, 6.86, 7.2, and 8.61 μM for USP4, USP8, USP7, USP2, and USP5, respectively. PR-619 induces ER Stress and ER-Stress related apoptosis .
loading...
    loading...
30
30 Cited Publications
Cat. No.: HY-14536
CAS No.: 61-73-4
Purity:  95.05%
Synonyms: Basic Blue 9; CI-52015; Methylthioninium chloride
Methylene blue (Basic Blue 9) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue is a Tau aggregation inhibitor. Methylene Blue is a photosensitizer and redox agent. Methylene blue reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation .
loading...
    loading...
27
27 Cited Publications
Cat. No.: HY-D0958
CAS No.: 122965-43-9
Synonyms: Basic Blue 9 hydrate; CI-52015 hydrate; Methylthioninium chloride hydrate
Methylene blue (Basic Blue 9) hydrate is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue hydrate through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue hydrate is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue hydrate is a Tau aggregation inhibitor. Methylene blue hydrate reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation .
loading...
    loading...
25
25 Cited Publications
Cat. No.: HY-13817
CAS No.: 314245-33-5
Purity:  99.30%
IU1 is a selective, reversible USP14 inhibitor with an IC50 of 4-5 μM. IU1 binds USP14’s catalytic cleft to block deubiquitinase activity. IU1 induces calpain-dependent Tau cleavage, causes ATP deficits, reduces E1~Ub thioester levels and 26S proteasome assembly. IU1 enhances 26S proteasome chymotrypsin-like activity, modulates LC3B-dependent autophagy flux, reduces cancer cell proliferation and migration, and blocks G0/G1 to S phase cell cycle transition in follicular thyroid cancer cells. IU1 activates autophagy-lysosomal and ubiquitin-proteasome pathways, triggers apoptosis, and reduces cervical cancer cell growth. IU1 enhances degradation of proteasome substrates linked to neurodegenerative disease, accelerates oxidized protein degradation, and increases oxidative stress resistance. IU1 can be used for the research of Alzheimer’s disease, follicular thyroid cancer, ischemic stroke, cervical cancer, and neurodegenerative disease .
loading...
    loading...
24
24 Cited Publications
Cat. No.: HY-N6785
CAS No.: 78111-17-8
Okadaic acid, a marine toxin, is an inhibitor of protein phosphatases (PP). Okadaic acid has a significantly higher affinity for PP2A (IC50=0.1-0.3 nM), and inhibits PP1 (IC50=15-50 nM), PP3 (IC50=3.7-4 nM), PP4 (IC50=0.1 nM), PP5 (IC50=3.5 nM), but does not inhibit PP2C. Okadaic acid increases of phosphorylation of a number of proteins by inhibiting PP, and acts a tumor promoter. Okadaic acid induces tau phosphorylation .
loading...
    loading...
24
24 Cited Publications
Cat. No.: HY-N6785A
CAS No.: 209266-80-8
Target:  

Phosphatase Apoptosis

Research Areas:  

Neurological Disease Cancer

Okadaic acid sodium, a marine toxin, is an inhibitor of protein phosphatases (PP). Okadaic acid (sodium) has a significantly higher affinity for PP2A (IC50=0.1-0.3 nM), and inhibits PP1 (IC50=15-50 nM), PP3 (IC50=3.7-4 nM), PP4 (IC50=0.1 nM), PP5 (IC50=3.5 nM), but does not inhibit PP2C. Okadaic acid sodium increases of phosphorylation of a number of proteins by inhibiting PP, and acts a tumor promoter. Okadaic acid sodium induces tau phosphorylation .
loading...
    loading...
24
24 Cited Publications
Cat. No.: HY-115760
CAS No.: 175522-42-6
Target:  

Phosphatase

Research Areas:  

Neurological Disease Cancer

Okadaic acid ammonium salt, a marine toxin, is an inhibitor of protein phosphatases (PP). Okadaic acid ammonium salt has a significantly higher affinity for PP2A (IC50=0.1-0.3 nM), and inhibits PP1 (IC50=15-50 nM), PP3 (IC50=3.7-4 nM), PP4 (IC50=0.1 nM), PP5 (IC50=3.5 nM), but does not inhibit PP2C. Okadaic acid ammonium salt increases of phosphorylation of a number of proteins by inhibiting PP, and acts as a tumor promoter. Okadaic acid ammonium salt induces tau phosphorylation .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-15136
CAS No.: 193275-84-2
Purity:  99.60%
Synonyms: Sch66336
Lonafarnib (Sch66336) is an orally active, blood-brain barrier penetrant farnesyltransferase (FPTase) inhibitor. Lonafarnib increases the phosphorylation levels of Akt, CaMKII and CREB, upregulates BDNF expression in the hippocampus, elevates the content of α7nAChR on cell membranes, and blocks the isoprenylation of H-Ras. Lonafarnib repairs synapses and reverses spatial memory deficits in Aβ1-42 model mice. Lonafarnib inhibits RSV fusion and replication, and alleviates virus-induced lung injury. Lonafarnib activates the lysosomal and autophagic pathways, and reduces the phosphorylation and aggregation of tau. Lonafarnib acts synergistically with Sorafenib (HY-10201) to promote apoptosis, and inhibits the proliferation and invasion of melanoma cells. Lonafarnib inhibits the farnesylation of progerin, repairs nuclear membrane defects, and activates the cGAS-STING-STAT1 signaling pathway. Lonafarnib can be used in research related to diseases including Alzheimer's disease, viral infections, melanoma, and progeria .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-12723
CAS No.: 58-00-4
Purity:  98.05%
Synonyms: (-)-Apomorphine
Apomorphine ((-)-Apomorphine) is a potent dopamine receptor agonist. Apomorphine also inhibit MAO-A and MAO-B. Apomorphine exerts neuroprotective effect and can relax rat corpus cavernosum. Apomorphine can inhibit ROS production, DNA fragmentation and inibit JNK and ERK1/2 phosphorylation. Apomorphine can enhance degradation of intracellular Aβ40 and Aβ42, reduces tau protein levels and inhibit MMP-9 expression. Apomorphine is a highly potent radical scavenger and iron chelator. Apomorphine can be used for the researches of dementia, parkinson's disease, alzheimer disease, breast carcinoma, and erectile dysfunction .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-19948
CAS No.: 1236208-20-0
Synonyms: TRx0237 mesylate; Methylene blue leuco base mesylate
Leucomethylene blue (TRx0237) mesylate, an orally active second-generation tau protein aggregation inhibitor (Ki of 0.12 μM), could be used for the study of Alzheimer's Disease. Leucomethylene blue mesylate is a common reduced form of Methylene Blue, Methylene Blue is a member of the thiazine class of dyes .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-103157
CAS No.: 4079-26-9
Purity:  99.59%
Synonyms: NSC168807
Target:  

Autophagy Ferroptosis

Research Areas:  

Cardiovascular Disease

PD146176 (NSC168807), a 15-Lipoxygenase (15-LO) inhibitor, inhibits rabbit reticulocyte 15-LO (Ki=197 nM, IC50=0.54 μM). PD146176 reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-N1472
CAS No.: 88182-33-6
Levistolide A is an apoptosis inducer and a PEDV virus inhibitor. Levistolide A can induce apoptosis in colon cancer cells and suppress the replication of porcine epidemic diarrhea virus (PEDV) by promoting ROS generation. Levistolide A activates peroxisome proliferator-activated receptor γ (PPARγ) in N2a/APP695swe cells and reduces excessive phosphorylation of tau through the GSK3α/β pathway, improving symptoms in Alzheimer’s mice. Levistolide A improves kidney damage in 5/6 nephrectomy (Nx) mice by inhibiting the RAS,TGF-β1/Smad, and MAPK pathways .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-145232
CAS No.: 3016307-75-5
Purity:  98.76%
Synonyms: OGTAC-3
Research Areas:  

Neurological Disease Cancer

PhosTAC7 is a heterobifunctional molecule named as a Phosphorylation Targeting Chimera (PhosTAC). PhosTAC7 can dephosphorylate the PDCD4 protein, FOXO3a protein, and tau protein by recruiting serine/threonine protein phosphatase 2A (PP2A). PhosTAC7 offers the advantage of selectively modulating the phosphorylation state of individual target proteins, making it a promising tool for research in cancer and tau protein-related neurodegenerative diseases (Alzheimer's disease) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-122243
CAS No.: 670270-31-2
Purity:  99.68%
Target:  

Deubiquitinase

Research Areas:  

Neurological Disease

IU1-47 is a potent and specific USP14 inhibitor with an IC50 of 0.6 μM. IU1-47 inhibits IsoT/USP5 with an IC50 of 20 μM. IU1-47 induces tau elimination in cultured neurons .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-128879A
CAS No.: 1281681-33-1
Purity:  98.01%
VP3.15 dihydrobromide is a highly potent, orally bioavailable, and CNS-penetrant PDE7-GSK3 dual inhibitor, with IC50 values of 1.59 μM and 0.88 μM against PDE7 and GSK3, respectively . VP3.15 dihydrobromide elevates intracellular cAMP levels, suppresses immune responses, enhances remyelination, limits excessive tau phosphorylation, and alleviates neuroinflammation and neuronal loss. VP3.15 dihydrobromide promotes oligodendrocyte precursor cell differentiation, improves in vivo remyelination, inhibits autoimmune encephalomyelitis, and mitigates germinal matrix-intraventricular hemorrhage-related brain injury, cerebral atrophy, ventricular enlargement, and cognitive impairment. VP3.15 dihydrobromide can be used in research related to multiple sclerosis and germinal matrix-intraventricular hemorrhage .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-101184
CAS No.: 1415379-56-4
Purity:  99.21%
Synonyms: AV-1451
Target:  

Tau Protein

Research Areas:  

Neurological Disease

T807 a novel tau positron emission tomography (PET) tracer.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P71798
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: IFNT1; Interferon TAU-1; IFN-TAU-1; Antiluteolysin; Trophoblast antiluteolytic protein; Trophoblast protein 1; TP-1; Trophoblastin
Species:  
Source:  
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P1675A
Synonyms: AcPHF6 TFA; Ac-VQIVYK-NH2 TFA
Target:  

Tau Protein

Research Areas:  

Neurological Disease

Acetyl-PHF6 amide TFA (AcPHF6 TFA) is a tau derived hexapeptide.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-12662
CAS No.: 1402727-29-0
Purity:  99.76%
Target:  

Microtubule/Tubulin

Research Areas:  

Neurological Disease

PE859 is a potent inhibitor of both tau and aggregation with IC50 values of 0.66 and 1.2 μM, respectively.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-122704A
CAS No.: 5424-37-3
Synonyms: Aminoquinuride dihydrochloride
Surfen dihydrochloride is a potent heparan sulfate antagonist. Surfen inhibits FGF2 binding and signal transduction. Surfen binds to glycosaminoglycans and reduces tau hyperphosphorylation. Surfen dihydrochloride inhibits the activity of recombinant uronyl 2-O-sulfotransferase with an IC50 of approximately 2 μM. Surfen dihydrochloride inhibits HSV-1 viral infection. Surfen dihydrochloride inhibits neural differentiation, delays remyelination, and alleviates EAE .
loading...
    loading...